top of page
Cure VCP Disease, Inc.

Introducing Dr. Zollie Yavarow: Our New Director of Scientific Engagement and Collaborations

We are thrilled to announce a significant addition to the Cure VCP Disease team. Please join us in welcoming Zollie Yavarow, PhD, MA, as our new Director of Scientific Engagement and Collaborations!

A profile picture of a professional
Dr. Zollie Yavarow

Academic Background and Expertise

Dr. Yavarow's impressive academic credentials include:

  • PhD in Pharmacology from Duke University

  • Master of Arts in Bioethics and Science Policy from Duke University

  • Postdoctoral Fellowship at COMBINEDBrain


Dr. Yavarow brings a unique blend of scientific expertise and patient advocacy to our organization. As a dedicated science communicator, she is committed to placing the patient perspective at the forefront of pharmaceutical development and regulatory decisions. Her interdisciplinary education equips her with a comprehensive understanding of both the scientific and ethical aspects of medical research and drug development.


"I'm excited to join Cure VCP Disease and to get to know the community. I look forward to working together on projects and making a difference for families impacted by VCP disease."

Dr. Yavarow's experience extends beyond academia. Her postdoctoral fellowship at COMBINEDBrain has provided her with valuable insights into collaborative research efforts. Furthermore, she has worked closely with various rare disease organizations, including the E.We Foundation, Cure LBSL, TESS Research Foundation, and USHER 1F Collaborative.

This extensive collaboration with rare disease communities has honed her ability to bridge the gap between scientific research and patient needs.


 

About the Initiatives at Cure VCP Disease:

As our Director of Scientific Engagement and Collaborations, Dr. Yavarow will spearhead several crucial initiatives:

1. Manage and expand our research programs, including:

  • Pre-clinical toolbox

  • Clinical trial readiness programs

2. Maintain and develop our scientific research agenda

3. Identify new scientific priorities for VCP disease research

4. Act as a liaison between:

  • Pre-clinical and clinical scientists

  • VCP disease patients and families

  • Governmental agencies

  • Biotech and pharmaceutical communities

 

Through these responsibilities, Dr. Yavarow will work to enhance collaborations and create meaningful impact for our VCP community. We are confident that Dr. Yavarow's expertise, experience, and dedication will be invaluable assets in our ongoing efforts to combat VCP disease. Please join us in giving her a warm welcome to our community!


74 views

コメント


bottom of page